Provectus Biopharmaceuticals, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Provectus Biopharmaceuticals, Inc. (PVCT) is a clinical-stage biotechnology company that develops immunotherapy medicines based on small molecules known as halogenated xanthenes for the treatment of diseases in oncology, dermatology, hematology, virology, microbiology, and ophthalmology. The company, founded in 2002 and headquartered in Knoxville, Tennessee, owns the entire class of these molecules, with its lead candidate rose bengal disodium formulated into products such as PV-10, an ablative immunotherapy for stage III and IV melanoma, liver cancers, blood cancers, relapsed and refractory pediatric solid tumors, bladder cancer, breast cancer, head and neck cancers, basal cell carcinoma, squamous cell carcinoma, and neuroendocrine tumors; PH-10 for psoriasis, atopic dermatitis, and skin inflammation; PV-305 for infectious keratitis; and additional oral, intranasal, and other formulations targeting adult solid tumor cancers, leukemias, severe acute respiratory syndrome coronavirus 2, gram-positive and gram-negative bacterial infections, oral bacterial infections, fungal infections, cutaneous canine cancers, full-thickness cutaneous wounds, wound healing, tissue regrowth, and antibiotic resistance. Provectus operates primarily in the United States through research collaborations and licensing agreements, targeting patients with life-threatening cancers and inflammatory skin conditions. Recent developments include the initiation of a preclinical study of oral PV-10 in bladder cancer in September 2025; a $3 million seed financing round in January 2025 for VisiRose, Inc., its founded entity developing novel ocular therapeutics; an exclusive worldwide license option agreement with the Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at the University of Miami for eye infection treatments; an exclusive license agreement with the University of Miami in April 2024 for photodynamic antimicrobial therapy in ophthalmology; research collaborations with the University of Texas Medical Branch at Galveston for wound healing, the University of Tennessee Health Science Center for antibiotic resistance, and the University of Calgary for oral rose bengal disodium in cancer treatment; and ongoing increases in research and development expenses to close out clinical trials as of December 2024.
Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
Provectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call Transcript
Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders
Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus's VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Up 16,004.0% in December
Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy
Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer
Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders
Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs
Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript
Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call